J. E. Norman

Medical abortion in women of ≤56 days amenorrhoea; a comparison between gemeprost (a PGE1 analogue) alone and mifepristone and gemeprost

Objective To determine the efficacy of a new dose regimen of vaginal gemeprost (l mg every 6 h up to three doses) in induction of abortion in women ≤56 days gestation, and to compare this regimen with mifepristone (200–600 mg) followed 48 h later by a single dose of gemeprost (l mg).

Misoprostol, mifepristone, and abortion

vancomycin-resistant strains were identified. In 20 of these patients the isolates indicated colonisation, but in the remaining 4, 1 was bacteraemic, 2 had colonisation of their central venous cannulas, and in 1 vancomycin-resistant E faecium was isolated from infected open surgical wounds. For all 24 isolates the minimum inhibitory concentrations (MICs) of vancomycin were 128-1024 mg/1, of teicoplanin 16-256 mg/1, and of ampicillin 64-256 mg/l. All isolates were resistant to erythromycin, clindamycin, rifampicin, ciprofloxacin, and imipenem. On Oct 10, the first of 4 patients was detected with vancomycinresistant isolates of E faecium that were also highly resistant to gentamicin (MICs > 1000 mg/1). 1 isolate was from a urinary catheter tip, one from a rectal swab, and two from central venous cannula tips. All 4 isolates were resistant to erythromycin, dindamycin, rifampicin, ciprofloxacin, and imipenem. The sensitivities to tetracycline, trimethoprim, and chloramphenicol